. . . . . . . "[WIN-R was an investigator-initiated trial in which patients with CHC received pegylated interferon ?-2b (1.5 ?g/kg/wk) plus a fixed ribavirin dose (800 mg/d) or a weight-based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:45+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .